MYLAN BARRED FROM SELLING GENERIC TOPAMAX

Published Online: Tuesday, May 1, 2007

A federal judge in New Jersey issued an injunction permanently barring Mylan Pharmaceuticals from selling generic topiramate tablets and capsules in the United States before September 26, 2008, the expiration date of the patent for TOPAMAX (topiramate) held by Ortho-McNeil Neurologics Inc. Mylan had challenged the validity of that patent and filed an abbreviated new drug application to market a generic version of the epilepsy drug. The branded manufacturer countered with a patent infringement complaint against Mylan and obtained a preliminary injunction against the generic firm last fall.




Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$
VSEO N/A